Glaucoma, Open-Angle Clinical Trial
Official title:
Non-inferiority Study for Visual Field Mean Defect Estimation Using Sequentially Optimized Reconstruction Strategy (SORS) With an OCTOPUS 900 Perimeter on Healthy and Glaucoma Subjects
NCT number | NCT03325751 |
Other study ID # | 2017-01540 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 1, 2018 |
Est. completion date | November 1, 2019 |
Verified date | January 2020 |
Source | University Hospital Inselspital, Berne |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Perimetry is a well-established method that is used to measure the visual field functions of
humans. Commercially available products, such as the OCTOPUS 900 (Haag-Streit AG, Koeniz,
Switzerland), are commonly used for assessing the visual field. Such devices are of critical
value for patients suffering of glaucoma and neuro-ophthalmic conditions. The operating
principle is to sequentially present light stimuli of different intensity at different
locations within the visual field in an automatic way. Algorithms that select what locations
and intensities to present over time are called strategies. These have the goal to provide
both a fast and accurate estimation of the visual field function.
Recently, new strategies were developed that are faster and equally accurate as the
strategies used today. The technological advancement of these new methods lies primarily in
the ability to estimate location sensitivities without observing them directly but by
leveraging previously queried locations. For this the investigators plan to implement the
next generation of perimetry strategies into an OCTOPUS 900 and to test it in healthy
subjects and glaucoma patients.
Status | Completed |
Enrollment | 103 |
Est. completion date | November 1, 2019 |
Est. primary completion date | August 2, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 40 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Cataract yes or no - Age range 40 - 80 years - Normal visual field (MD: < +2 dB) - Refractive error within ±5 dpt. spherical equivalent - Astigmatism of < -3 dpt. - Visual acuity of =0.3 logMar (decimal =0.5) - Experience in perimetry (history of at least one perimetry examination) - False positive or negative errors each less than 20% in each examination - Primary open-angle/ pseudoexfoliation/ primary angle-closure glaucoma - Early to moderate visual field loss (MD: +2 to +12 dB) - Written informed consent Exclusion Criteria: Exclusion criteria are children (<18 years old), inability to follow the procedure, insufficient knowledge of project language, the history of other ocular diseases than glaucoma or cataract or other conditions that might affect visual field testing (e.g. pituitary lesions, demyelinating diseases). |
Country | Name | City | State |
---|---|---|---|
Switzerland | Department of Ophthalmology, Inselspital, University Hospital Bern | Bern |
Lead Sponsor | Collaborator |
---|---|
University Hospital Inselspital, Berne | University of Bern |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Non-inferiority estimation quality of mean defect between SORS and dynamic strategy visual field locations | The primary endpoint of this study is the non-inferiority estimation quality of mean defect when using SORS visual field locations as compared to the dynamic strategy visual field locations in healthy subjects and glaucoma patients with early or moderate visual field loss. The non-inferiority margin is defined as a mean defect difference of no more than 0.5 decibel to the dynamic strategy measurement. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05044793 -
A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System
|
||
Recruiting |
NCT06201455 -
Evaluation of Phacogoniotomy in Medically-controlled POAG
|
N/A | |
Recruiting |
NCT03369886 -
The Relationship Between Macular OCTA and GCIPL and Their Combinational Index Using AI
|
N/A | |
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Recruiting |
NCT02679482 -
Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma
|
N/A | |
Completed |
NCT02338362 -
Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma
|
Phase 4 | |
Active, not recruiting |
NCT01430923 -
Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost
|
N/A | |
Completed |
NCT01489670 -
Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension
|
N/A | |
Completed |
NCT00693485 -
Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy
|
Phase 2 | |
Completed |
NCT00753168 -
Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma
|
Phase 1/Phase 2 | |
Completed |
NCT00051194 -
A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension
|
Phase 2 | |
Recruiting |
NCT04920227 -
Comparation of CLASS Combined With Phacoemulsification and CLASS Alone in the Treatment of Primary Open Angle Glaucoma
|
N/A | |
Active, not recruiting |
NCT03868124 -
Clinical Study Comparing Two Models of a Travoprost Intraocular Implant
|
Phase 3 | |
Completed |
NCT03267862 -
Scleral Response to Intraocular Pressure (IOP)
|
N/A | |
Recruiting |
NCT06066645 -
Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone
|
Phase 3 | |
Recruiting |
NCT04912362 -
The Effectiveness of YAG Iridotomy in Preventing Peripheral Anterior Synechia After CLASS in Primary Open Angle Glaucoma
|
N/A | |
Completed |
NCT04949802 -
Glaucoma Surgery Using the ViaLase Laser System
|
N/A | |
Recruiting |
NCT04038034 -
Valuation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) in Patients Affected by Primary Open Angle Glaucoma
|
N/A | |
Completed |
NCT04632329 -
Negative Pressure Applied by the Equinox MPD for Severe Open Angle Glaucoma
|
N/A | |
Completed |
NCT01215786 -
Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
|
Phase 1 |